Methods and systems for characterizing severe Crohn's disease
AssigneeCedars-Sinai Medical Center
InventorsDermot P. Mcgovern, Dalin Li, Phillip Gu, Shishir Dube, Talin Haritunians, Marzieh Akhlaghpour
Life of this patent
Estimating the term…
Abstract
The present disclosure describes methods, devices and systems of diagnosing, prognosing, and treating subjects with moderate to severe forms of Crohn's disease (CD) that is characterized by stricturing and internal penetrating disease phenotypes. Also described are methods and kits for characterizing a subtype of CD, and identifying a subject as being suitable for a therapy to treat the CD.
Claims16
A method of treating Crohn's disease (CD) in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-tumor necrosis factor ligand 1A (anti-TL1A) antibody, wherein the subject has at least one polymorphism selected from the group consisting of rs112668709A, rs66863235G, rs570462G, rs568675G, rs476148A, rs474188C, rs1579609G, rs1579610C, rs9402929G, rs6722613G, rs11161618A, rs17456596G, rs177665C, rs2314737G, rs351758A, rs4325270T, rs445417A, rs525850A, rs6074737A, rs635624C, rs658795A, rs666478G, rs684093G, rs7130717G, rs7416358G, rs768755T, rs7774349A, and rs936126A, and wherein the subject has non-stricturing and non-penetrating CD, and wherein the anti-TL1A antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 356 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 357.
Dependencies are inferred from the claim text.